Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil

Abstract

Mutated forms of p53 are often expressed in a variety of human tumors. In addition to loss of function of the p53 tumor suppressor, mutant p53s contribute to malignant process by acquisition of novel functions that enhance transformed properties of cells and resistance to anticancer therapy in vitro, and increase tumorigenecity, invasiveness and metastatic ability in vivo. Searching for genes that change expression in response to p53 gain of function mutants may give a clue to the mechanisms underlying their oncogenic effects. Recently by subtraction hybridization cloning we found that the dUTPase gene is transcriptionally upregulated in p53-null mouse fibroblasts expressing the exogenous human tumor-derived His175 p53 mutant. Here we show that conditional expression of His175 and Trp248 hot-spot p53 mutants in p53-negative mouse 10(1) fibroblasts and human SK-OV3 and H1299 tumor cells results in increase in dUTPase gene transcription, an important marker predicting the efficacy of cancer therapy with fluoropyrimidine drugs. Using tetracycline-regulated retroviral vectors for conditional expression of p53 mutants, we found that transcription of the dUTPase gene is increased within 24 h after tetracycline withdrawal, and the cells acquire higher resistance to 5-FU. Additional inactivation of the N-terminal transcription activation domain of mutant p53 (substitutions in amino-acid residues 22 and 23) results in abrogation of both induction of dUTPase transcripts and 5-FU resistance.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Aherne GW, Browne S . 1999 Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy Jackman AL (ed) Totowa, NJ: Humana Press, Inc pp 409–421

    Book  Google Scholar 

  • Benhattar J, Cerottini JP, Saraga E, Metthez G, Givel JC . 1996 Int. J. Cancer 69: 190–192

  • Blandino G, Levine AJ, Oren M . 1999 Oncogene 18: 477–485

  • Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F, Filippini L, Betri E, Bertoli G, Alquati P, Dogliotti L . 2000 Clin. Cancer Res. 6: 2751–2758

  • Bunz L, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B . 1999 J. Clin. Invest. 104: 263–269

  • Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier AM, Soussi T, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P . 2000 J. Clin. Oncol. 18: 1465–1473

  • Canman CE, Radany EH, Parsels LA, Davis MA, Lawrence TS, Maybaum J . 1994 Cancer Res. 54: 2296–2298

  • Chin KV, Ueda K, Pastan I, Gottesman MM . 1992 Science 255: 459–462

  • Deb S, Jackson CT, Subler MA, Martin DW . 1992 J. Virol. 66: 6164–6170

  • Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ . 1993 Nat. Genet. 4: 42–46

  • Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS, Bradley A . 1992 Nature 356: 215–221

  • el-Deiry WS . 1998 Semin. Cancer Biol. 8: 345–357

  • Frazier MW, He X, Wang J, Gu Z, Cleveland JL, Zambetti GP . 1998 Mol. Cell. Biol. 18: 3735–3743

  • Gloushankova N, Ossovskaya V, Vasiliev J, Chumakov P, Kopnin B . 1997 Oncogene 15: 2985–2989

  • Gossen M, Bujard H . 1992 Proc. Natl. Acad. Sci. USA 89: 5547–5551

  • Greenblatt MS, Bennett WP, Hollstein M, Harris CC . 1994 Cancer Res. 54: 4855–4878

  • Harvey DM, Levine AJ . 1991 Genes Dev. 5: 2375–2385

  • Hsiao M, Low J, Dorn E, Ku D, Pattengale P, Yeargin J, Haas M . 1994 Am. J. Pathol. 145: 702–714

  • Kelavkar UP, Badr KF . 1999 Proc. Natl. Acad. Sci. USA 96: 4378–4383

  • Kopnin BP, Stromskaya TP, Kondratov RV, Ossovskaya VS, Pugacheva EN, Rybalkina EY, Khokhlova OA, Chumakov PM . 1995 Oncol. Res. 7: 299–306

  • Kremenetskaya OS, Logacheva NP, Baryshnikov AY, Chumakov PM, Kopnin BP . 1997 Oncol. Res. 9: 155–166

  • Ladner RD, Lynch FJ, Groshen S, Xiong YP, Sherrod A, Caradonna SJ, Stoehlmacher J, Lenz HJ . 2000 Cancer Res. 60: 3493–3503

  • Lanyi A, Deb D, Seymour RC, Ludes-Meyers JH, Subler MA, Deb S . 1998 Oncogene 16: 3169–3176

  • Levine AJ . 1997 Cell 88: 323–331

  • Levine AJ, Wu MC, Chang A, Silver A, Attiyeh EF, Lin J, Epstein CB . 1995 Ann. NY Acad. Sci. 768: 111–128

  • Li R, Sutphin PD, Schwartz D, Matas D, Almog N, Wolkowicz R, Goldfinger N, Pei H, Prokocimer M, Rotter V . 1998 Oncogene 16: 3269–3277

  • Lin J, Teresky AK, Levine AJ . 1995 Oncogene 10: 2387–2390

  • Lindhal T . 1982 Annu. Rev. Biochem. 51: 61–87

  • Liu G, McDonnell TJ, Montes de Oca Luna R, Kapoor M, Mims B, El-Naggar AK, Lozano G . 2000 Proc. Natl. Acad. Sci. USA 97: 4174–4179

  • Lotem J, Sachs L . 1995 Proc. Natl. Acad. Sci. USA 92: 9672–9676

  • Matas D, Sigal A, Stambolsky P, Milyavsky M, Weisz L, Schwartz D, Goldfinger N, Rotter V . 2001 EMBO J. 20: 4163–4172

  • Michalovitz D, Halevy O, Oren M . 1991 J. Cell Biochem. 45: 22–29

  • Peled A, Zipori D, Rotter V . 1996 Cancer Res. 56: 2148–2156

  • Pugacheva EN, Snegur IN, Kopnin BP, Chumakov PM . 2000 Mol. Biol. 34: 143–151

  • Sambrook J, Fritsch E, Maniatis T . 1989 Molecular Cloning New York: Cold Spring Harbor Laboratory Press

    Google Scholar 

  • Sionov RV, Moallem E, Berger M, Kazaz A, Gerlitz O, Ben-Neriah Y, Oren M, Haupt Y . 1999 J. Biol. Chem. 274: 8371–8374

  • Sun Y, Nakamura K, Wendel E, Colburn N . 1993 Proc. Natl. Acad. Sci. USA 90: 2827–2831

  • Tsutsumi-Ishii Y, Tadokoro K, Hanaoka F, Tsuchida N . 1995 Cell Growth Differ. 6: 1–8

  • Wolf D, Harris N, Rotter V . 1984 Cell 38: 119–126

  • Yang X, Pater A, Tang SC . 1999 Oncogene 18: 4546–4553

  • Zheng M, Wang H, Zhang H, Ou Q, Shen B, Li N, Yu B . 1999 J. Cancer Res. Clin. Oncol. 125: 357–360

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Peter M Chumakov.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pugacheva, E., Ivanov, A., Kravchenko, J. et al. Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil. Oncogene 21, 4595–4600 (2002). https://doi.org/10.1038/sj.onc.1205704

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205704

Keywords

This article is cited by

Search

Quick links